Finoriq research workspace
Xilio Therapeutics, Inc. (XLO) Historical Metrics
Xilio Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery. Review XLO fundamentals, ratios, and historical filing metrics on Finoriq.
Company Snapshot
Xilio Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of masked immuno-oncology therapies. The company's pipeline includes XTX501, a bispecific PD-1 / masked IL-2, for patients with metastatic non-small cell lung cancer; Efarindodekin alfa, an investigational, masked IL-12, that is in Phase 2 clinical trial for patients with advanced solid tumors; and Vilastobart, an investigational tumor-activated, Fc-enhanced, high affinity binding anti-CTLA-4 monoclonal antibody. The company was founded in 2016 and is headquartered in Waltham, Massachusetts.
- Company
- Xilio Therapeutics, Inc. (XLO)
- Ticker
- XLO
- Market Cap
- $56.2M
- Latest Price
- $8.545
- Industry
- Biotech & Pharma
Xilio Therapeutics, Inc. (XLO) Current Valuation Metrics
Static valuation preview for Xilio Therapeutics, Inc. (XLO). Market data retrieved 2026-07-09. Filing currency USD.
| Metric | Value | Source |
|---|---|---|
| P/SMarket cap divided by latest TTM revenue. | 1.38x | Revenue | TTM FY 2025 |
| Earnings YieldLatest TTM net income divided by market cap. | -58.2% | Net Income | TTM FY 2025 |
| Operating Cash Flow YieldLatest TTM operating cash flow divided by market cap. | -8.3% | Operating Cash Flow | TTM FY 2025 |
| Price / BookMarket cap divided by stockholders' equity. | 1.71x | Stockholders' Equity | FY 2025 |
Live data loads in the app
This static page shell gives search engines reliable page context. Current tables, filings, charts, and market data continue to load from Finoriq APIs after the application starts.